Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms

Preclinical Study Summary GHK-Cu has been investigated in skin biology research, wound healing models, hair follicle studies, and bone tissue research
doi:10.1152/japplphysiol.00945.2010 Sikiric P, Blagaic AB, Strbe S, et al
No external party paid for, sponsored, or had editorial input into this article
Subsequent research has revealed its effects may be more complex and potentially extend beyond sleep regulation